Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Medroxyprogesterone may help shrink or slow the growth of kidney cancer.
Interferon may interfere with the growth of tumor cells. Aldesleukin may stimulate white
blood cells to kill tumor cells. It is not yet known whether giving medroxyprogesterone,
interferon, or aldesleukin alone is more effective than giving interferon together with
aldesleukin in treating kidney cancer.
PURPOSE: This randomized phase III trial is studying medroxyprogesterone, interferon, or
aldesleukin to see how well they work when given alone compared to interferon combined with
aldesleukin in treating patients with metastatic kidney cancer.